Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 4INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 6Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Colorectal Neoplasms 4Neoplasm Metastasis 3Colonic Neoplasms 3Thymoma 2Rectal Neoplasms 2Neoplasms 2Mesothelioma, Malignant 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Basal Cell 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Tobacco Use Disorder 1Temporomandibular Joint Disorders 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Smoking 1Small Cell Lung Carcinoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasm, Residual 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Mesothelioma 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Specimen Handling 3Biopsy 3Endoscopy, Gastrointestinal 2obeticholic acid 1Surveys and Questionnaires 1Sigmoidoscopy 1Gastroscopy 1Erlotinib Hydrochloride 1Endoscopy, Digestive System 1Eflornithine 1Curcumin 1Colonoscopy 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenomatous Polyposis Coli × Celecoxib × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡